- Prescribing Advice for GPs - https://www.prescriber.org.uk -

NICE Guidance - December 2019

The National Institute for Health and Care Excellence (NICE) have published new or updated guidance for the month of December 2019. This month there are two guidelines and two technology appraisals that impact upon primary care.

The Acute kidney injury: prevention, detection and management guideline has been published. It covers preventing, detecting and managing acute kidney injury in children, young people and adults. It aims to improve assessment and detection by non-specialists, and specifies when people should be referred to specialist services. This will improve early recognition and treatment, and reduce the risk of complications in people with acute kidney injury.

The Menopause: diagnosis and management guideline has been updated. It covers the diagnosis and management of menopause, including in women who have premature ovarian insufficiency. The guideline aims to improve the consistency of support and information provided to women in menopause. This update includes MHRA safety alert information regarding the risks of breast cancer.

The Cannabidiol with clobazam for treating seizures associated with Dravet syndrome technology appraisal recommends this treatment as an option for treating seizures associated with Dravet syndrome in people aged 2 years and older, only if:

The Cannabidiol with clobazam for treating seizures associated with Lennox–Gastaut syndrome technology appraisal recommends this treatment as an option for treating seizures associated with Lennox–Gastaut syndrome in people aged 2 years and older, only if:

Action: Clinicians should be aware of this month's new guidance and implement any necessary changes to practice.